[Electrophysiologic effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation].
D000284:Administration, Oral; D000813:Anilides / Q000008:administration & dosage*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D016700:Encainide; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D016700:Encainide
Effetti elettrofisiologici dell'encainide endovenosa ed orale in pazienti con sindrome di Wolff-Parkinson-White e fibrillazione atriale parossistica.